Tarsus Pharmaceuticals (TARS) EBITDA (2019 - 2026)

Tarsus Pharmaceuticals' EBITDA history runs 8 years deep, the most recent figure standing at -$6.1 million for Q1 2026.

• On a quarterly basis, EBITDA rose 76.7% year-over-year to -$6.1 million in Q1 2026; TTM through Mar 2026 was -$50.8 million, a 53.45% increase from a year earlier, with the FY2025 full-year figure at -$71.0 million, up 41.14% from the prior year.
• EBITDA rose to -$6.1 million in Q1 2026 per TARS's latest filing, from -$8.0 million in the prior quarter.
• Across five years, EBITDA topped out at -$5.2 million in Q2 2022 and bottomed at -$44.4 million in Q4 2023.
• The 5-year median for EBITDA is -$24.4 million (2024), against an average of -$23.7 million.
• Across the five-year window, EBITDA tumbled 528.27% in 2023 and soared 76.7% in 2026, its largest moves.
• Year by year, EBITDA stood at -$15.1 million in 2022, then plunged by 195.13% to -$44.4 million in 2023, then surged by 45.06% to -$24.4 million in 2024, then soared by 67.34% to -$8.0 million in 2025, then gained by 23.24% to -$6.1 million in 2026.
• Per Business Quant, the three latest TARS EBITDA figures stand at -$6.1 million (Q1 2026), -$8.0 million (Q4 2025), and -$14.5 million (Q3 2025).